The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control their blood glucose level.
Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S).
Date of review: February 2016
The California Technology Assessment Forum (CTAF) held a public meeting in February 2016 to discuss the comparative effectiveness and value of a drug for patients with diabetes (type 1 and type 2). The diabetes drug, insulin degludec (Tresiba®, Novo Nordisk), is a long-acting basal insulin that patients inject once per day.
Research protocol posted to Open Science Framework: https://osf.io/7awvd/
ICER’s response to public comments received on the draft report and voting questions on insulin degludec for the treatment of diabetes.